Amherst College, Amherst, MA, USA.
Transl Stroke Res. 2013 Feb;4(1):56-62. doi: 10.1007/s12975-012-0235-0. Epub 2013 Jan 8.
Activation and repression of gene expression are key features of ischemic tolerance. Converging lines of inquiry from several groups suggests that epigenetic proteins may transduce sublethal stresses, including bioenergetic or oxidative stress into durable (2-3 days) changes in gene expression that mediate ischemic tolerance. Here we discuss the potential mechanisms by which changes in cell state (e.g., ATP, NAD+, and oxygen) can modify specific targets including polycomb complexes, jumonji domain histone demethylases, and zinc and NAD-dependent histone decetylases and thus trigger an adaptive program. A major unanswered question is whether these proteins work in parallel or convergently as part of a "tolerosome" (tolero is the Latin word for tolerance), a multiprotein complex recruited to promoters or enhancers of specific genes, to mediate preconditioning. Whatever the case may be, epigenetic proteins are fertile targets for the treatment of stroke.
基因表达的激活和抑制是缺血耐受的关键特征。来自几个研究小组的汇聚研究表明,表观遗传蛋白可能将亚致死应激(包括能量代谢或氧化应激)转导为持久(2-3 天)的基因表达变化,从而介导缺血耐受。在这里,我们讨论了细胞状态变化(例如,ATP、NAD+和氧气)如何修饰特定靶标(包括多梳复合物、组蛋白去甲基酶、锌和 NAD 依赖性组蛋白去乙酰化酶)的潜在机制,从而触发适应性程序。一个尚未解决的主要问题是,这些蛋白是否作为“耐受体”(tolero 是拉丁语中“耐受”的意思)的一部分平行或会聚工作,耐受体是一种招募到特定基因启动子或增强子的多蛋白复合物,以介导预处理。无论哪种情况,表观遗传蛋白都是治疗中风的有前途的靶点。